Figure 3 | Scientific Reports

Figure 3

From: Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies

Figure 3

Impact of TL-895 on the ADCC of anti-PD-L1 and anti-EGFR (C225) antibodies. Conducted in two target cell lines (A431 and A549), where panel (a) shows single concentrations (20 ng/mL) of anti-PD-L1 and anti-EGFR (C225) antibodies with a range of concentrations of TL-895; panels (b) and (c) show 0.05 or 3 µM TL-895 with a range of concentrations of anti-PD-L1 antibody and anti-EGFR antibody, respectively. ADCC antibody-dependent cell-mediated cytotoxicity, EGFR epidermal growth factor receptor, PD-L1 programmed death-ligand 1.

Back to article page